Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

Main Content

On Demand Series

UPDATE: Treating COVID-19 in PD and other movement disorders: a review of drug interactions

Length:30 MinutesCME Credits:1Release Date:Jun 05, 2020

Experienced / IntermediateExpert / AdvancedOn Demand Series

Program Description

The Treating COVID-19 in PD and other movement disorders: a review of drug interactions webinar will discuss possible pharmacological interactions between experimental COVID-19 drugs and the established treatments used in PD, tremor, dystonia, chorea and tics. Further, this course will provide guidelines to Movement Disorders specialists as well as general neurologists to ensure that their patients with COVID-19 are treated safely. Necessary drug adjustments will be discussed for each movement disorder drug and also for drugs that are commonly used to treat non motor symptoms in movement disorder patients such as GI problems, psychiatric comorbidities, dementia, and insomnia. Finally, some clinical cases will be put forth to discuss potential problems and possible solutions.

As the number of people infected by SARS-CoV-2 continues to rise, it is our responsibility to learn how this universal health crisis can impact Movement Disorder patients’ care. There are a number of experimental treatments being used to treat COVID-19, based on repurposed drugs and more recent antivirals and inmunomodulators. The mechanisms of action and side effects of these drugs vary widely and may interact with treatments of some neurological disorders, such as Parkinson’s disease and other movement disorders. To date, there is no data suggesting that PD, or any other movement disorder, increases the risk of developing COVID-19. However, movement disorder patients may have an increased risk of infection if living in nursing homes and may develop severe disease due to advanced age or comorbid diseases (i.e. hypertension or diabetes).

Faculty

Mónica M. Kurtis, MD ; Pablo Mir, MD, PhD ;

Course Purpose

The primary purpose of this program is to provide information on treading COVID-19 in Parkinson's disease patients.

Learning Objectives

Upon completion of this activity learners will be able to:
1. Identify possible interactions between COVID-19 drugs and PD medication
2. Adjust dopaminergic therapy in PD patients with COVID-19
3. Provide safe and accurate information to patients and other physician during the COVID-19 pandemic

Intended Audience

This activity is intended for Movement Disorders specialists, Movement Disorders fellows, general neurologists, neurology residents, and general practitioners.

Accreditation Credit

The International Parkinson and Movement Disorder Society designates this education activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Method of Participation

The course must be attended in their entirety. Partial credit is not available. If you are seeking continuing education credit for a specialty not listed in the Accreditation Statement, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.

Faculty Disclosure

DRUG20WEB2-Disc

Staff Disclosure

MDS staff members involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Hardware and Software Requirements

1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher).
5. Adobe Reader to print certificate.

Contact Us

Allie Oakley

Disclaimer

All individuals in control of content for this course are required to disclose all relevant financial relationships with commercial interests as defined by the ACCME.

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including mds.movementdisorders.org and mds.execinc.com. This cookie policy only covers the primary movementdisorders.org and mdscongress.org domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice